Clinical trials: Vascular Tumor
Multiple Myeloma
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
This is a research study to see if a new drug called bortezomib is useful to treat multiple myeloma in people who are newly diagnosed, and have not yet received treatment for their disease.
- Trial name
- NCT01090921
- Testing
- Bortezomib
- Where
- 11 sites in United States
- Volunteers
- 50 people
- Sponsor
- Boston VA Research Institute, Inc.
Multiple Myeloma, Plasma Cell Neoplasm
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Patients with previously treated multiple myeloma and kidney dysfunction will be treated with lenalidomide and low-dose dexamethasone.
- Trial name
- PrE1003 (NCT00790842)
- Testing
- Lenalidomide, Dexamethasone, Anticoagulants
- Where
- 16 sites in United States
- Volunteers
- 63 people
- Sponsor
- PrECOG, LLC.
Multiple Myeloma, Plasma Cell Neoplasm
Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction
RATIONALE: Antibodies, such as human immune globulin, can block the growth of abnormal cells in different ways. Some block the ability of abnormal cells to grow and spread.
- Trial name
- NCT00547365
- Testing
- Human immune globulin intravenous (IGIV)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Tennessee
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
This phase II trial studies how well panobinostat, carfilzomib, and dexamethasone work in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory).
- Trial name
- NCT03256045
- Testing
- Carfilzomib, Chemosensitivity Assay, Dexamethasone
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Washington
Cancer, Neoplasms
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
This is an open-label, multicenter, 2-part study to determine the recommended Phase 2 dose (RP2D) for GSK2816126 given twice weekly by intravenous (IV) infusion.
- Trial name
- NCT02082977
- Testing
- GSK2816126
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
The purpose of this study is to improve the clinical outcomes of research subjects with high-risk multiple myeloma in the context of the immediately preceding Total therapy 5 trial 2008-02 and Total therapy 3 trials 2003-33 and…
- Trial name
- NCT02128230
- Testing
- myPRS, Induction 1 - MEL-10+CFZ-TD-PACE, First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Arkansas
Multiple Myeloma
To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
This study will evaluate the safety and tolerability profile of belantamab mafodotin when administered in combination with approved regimens of either Lenalidomide Plus Dexamethasone [Len/Dex (Treatment A)] or Bortezomib Plus…
- Trial name
- DREAMM 6 (NCT03544281)
- Testing
- Belantamab mafodotin, Lenalidomide, Dexamethasone
- Where
- 26 sites in United States, Australia and 3 more
- Volunteers
- 153 people
- Sponsor
- GlaxoSmithKline
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
This phase II trial studies how well ixazomib citrate works in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) but is not resistant to bortezomib (refractory).
- Trial name
- NCT01415882
- Testing
- Cyclophosphamide, Daratumumab, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 165 people
- Sponsor
- Mayo Clinic
Waldenstrom's Macroglobulinemia
CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia
The purpose of this study is to determine the number of patients with Waldenstrom's macroglobulinemia that will benefit from treatment with CC-5103 (lenalidomide) and rituximab, what the side effects are and how long the benefit…
- Trial name
- NCT00142168
- Testing
- CC-5103 (lenalidomide), Rituximab
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
RATIONALE: Giving chemotherapy before a donor umbilical cord blood transplant (UCBT) helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT01093586
- Testing
- double-unit umbilical cord blood transplantation, cytogenetic analysis, bone marrow aspiration
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Case Comprehensive Cancer Center
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
This phase II MATCH treatment trial identifies the effects of crizotinib in patients whose cancer has a genetic change called ALK rearrangement.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439266
- Testing
- Crizotinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Subclinical Hypercortisolism, Cushing Syndrome
Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism
Background: Adrenal tumors are a common kind of tumor. Some of these secrete extra cortisol into the body, which can lead to diabetes, obesity, and other diseases.
- Conditions
- Subclinical Hypercortisolism, Cushing Syndrome, Adrenal Neoplasm
- Trial name
- NCT02001051
- Testing
- Adrenalectomy, Observation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma and Plasma Cell Neoplasm
Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
RATIONALE: Giving high-dose chemotherapy before an autologous stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00941720
- Testing
- busulfan, cyclophosphamide, autologous hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Case Comprehensive Cancer Center
Multiple Myeloma, Smoldering Multiple Myeloma
Imaging in MGUS, SMM and MM
Background: Recent studies have shown that the premalignant conditions monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) have a high risk of progressing to multiple myeloma (MM).
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
- Trial name
- NCT01237054
- Testing
- 18-NaF PET, DCE-MRI, 18-FDG PET/CT
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Myeloma
Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant
The goal of this clinical research study is to learn if vaccinating a donor with your purified myeloma protein and then injecting it back into you will help your immune system control the multiple myeloma.
- Trial name
- NCT01174082
- Testing
- KLH Vaccine, KLH-id Vaccine, GM-CSF
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
This phase I/II trial is studying the side effects and best dose of vorinostat when given together with rituximab, ifosfamide, carboplatin, and etoposide and to see how well they work in treating patients with relapsed or…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Contiguous Stage II Mantle Cell Lymphoma
- Trial name
- NCT00601718
- Testing
- vorinostat, rituximab, ifosfamide
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Washington
Stage I Multiple Myeloma, Stage II Multiple Myeloma
Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
This phase II trial studies side effects and how well bendamustine hydrochloride, bortezomib, and dexamethasone work in treating patients with newly diagnosed multiple myeloma.
- Conditions
- Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT02224729
- Testing
- Bendamustine hydrochloride, Bortezomib, Dexamethasone
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Multiple Myeloma
Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant
This study will enroll myeloma subjects undergoing autotransplantation. The primary objective of this study is to evaluate whether infusions of Id-KLH primed CD3/CD28 activated autologous lymphocytes mediate a more intense…
- Trial name
- NCT01426828
- Testing
- CD3/CD28
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Pennsylvania
Sarcoma
Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
- Trial name
- STRASS (NCT01344018)
- Testing
- therapeutic conventional surgery, 3-dimensional conformal radiation therapy
- Where
- 37 sites in United States, Belgium and 11 more
- Volunteers
- 266 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Arterial Thromboembolism, Venous Thromboembolism
Long-term Active Surveillance Study for Oral Contraceptives (LASS)
The objective of this study is to characterize and compare the risks of long-term use of oral contraceptives containing drospirenone and of other established oral contraceptives.
- Conditions
- Arterial Thromboembolism, Venous Thromboembolism, Breast Cancer
- Trial name
- NCT00676065
- Where
- Germany
- Volunteers
- 58,303 people, healthy volunteers welcome
- Sponsor
- Center for Epidemiology and Health Research, Germany